ArticleJournal of inflammation research2026
Gan-Pi-Tong-Zhi Decoction Ameliorates OVA-Induced Asthma Through MAPK and Nrf2 Signaling Pathways and Regulating Gut Microbiota.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the therapeutic mechanism of Gan-Pi-Tong-Zhi Decoction (GPTZ) in asthma. Methods: The study explored the chemical components of GPTZ by using UPLC-Q-TOF-MS, and utilized the database for target identification, and predicted potential pathways using network pharmacology. The protective effects of GPTZ against asthma were assessed by measuring levels of inflammatory factors and biochemical markers related to oxidative stress. 16S rRNA gene sequencing was used to explore the underlying mechanism of GPTZ against asthma through gut-lung axis, while quantitative PCR (qPCR) analyses, Western blot, and immunohistochemistry were used to identify targets within key signaling pathways. Results: A total of 25 components in GPTZ were identified. Network pharmacology analysis revealed 150 common targets through which GPTZ may treat asthma via the gut-lung axis. Enrichment analysis indicated that the therapeutic effects of GPTZ are related to its regulation of MAPK and Nrf2 signaling pathways. These findings were further supported by experimental validation at both the gene and protein expression levels. In OVA-induced asthmatic rats, GPTZ administration alleviated asthma symptoms, reduced systemic inflammation, and mitigated pathological damage in lung and colon tissues. Treatment with GPTZ ameliorated microbial dysbiosis at both phylum and genus levels, while enhancing the functional capacity of the gut microbiota. Additionally, it markedly inhibited the release of TNF-α, IL-6, and IL-1β, elevated the activities of antioxidant enzymes such as glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT), and decreased malondialdehyde (MDA). Conclusion: GPTZ effectively alleviates asthma. The mechanism lies in inhibiting the inflammatory response mediated by MAPK signaling pathway and activating the antioxidant response mediated by Nrf2 signaling pathway. This protective effect may be potentially associated with the maintenance of gut microbiota homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.